Disseminated intravascular coagulation complicating mild or asymptomatic maternal COVID-19.

SARS-CoV-2 placentitis decreased fetal movement intrauterine fetal demise massive transfusion placental fibrinoid deposition placental histiocytic intervillositis placental necrosis stillbirth

Journal

AJOG global reports
ISSN: 2666-5778
Titre abrégé: AJOG Glob Rep
Pays: United States
ID NLM: 101777907

Informations de publication

Date de publication:
Nov 2022
Historique:
pubmed: 29 9 2022
medline: 29 9 2022
entrez: 28 9 2022
Statut: ppublish

Résumé

Hypercoagulability frequently complicates moderate or severe COVID-19 and can result in venous thromboembolism, arterial thrombosis, or microvascular thrombosis. Disseminated intravascular coagulation, however, is uncommon. We sought to describe the clinical presentation and outcome in a series of pregnant patients with mild or asymptomatic COVID-19 who had disseminated intravascular coagulation. This was a retrospective case series. Cases were solicited via e-mails targeted to obstetrical providers in the Mednax National Medical Group and a restricted maternal-fetal medicine Facebook page. Inclusion criteria were: hospital admission during pregnancy, positive test for SARS-CoV-2 within 2 weeks of admission, and maternal disseminated intravascular coagulation defined as ≥2 of the following: platelet count ≤100,000 per mm Inclusion criteria were met in 19 cases from October 2020 through December 2021. Of these, 18 had not received any COVID-19 vaccine, and 1 had unknown vaccination status. Median gestational age on hospital admission was 30 weeks (interquartile range, 29-34 weeks). The main presenting symptom or sign was decreased fetal movement (56%) or nonreassuring fetal heart rate pattern (16%). COVID-19 was asymptomatic in 79% of cases. Two of the 3 defining coagulation abnormalities were found in 89% of cases and all 3 in the remaining 11%. Aspartate aminotransferase was elevated in all cases and ≥2 times the upper normal limit in 69%. Only 2 cases (11%) had signs of preeclampsia other than thrombocytopenia or transaminase elevation. Delivery was performed on the day of admission in 74% and on the next day in the remaining 26%, most often by cesarean delivery (68%) under general anesthesia (62%) because of nonreassuring fetal heart rate pattern (63%). Postpartum hemorrhage occurred in 47% of cases. Blood product transfusions were given in 95% of cases, including cryoprecipitate (89% of cases), fresh/frozen plasma (79%), platelets (68%), and red cells (63%). Placental histopathology was abnormal in 82%, with common findings being histiocytic intervillositis, perivillous fibrin deposition, and infarcts or necrosis. Among the 18 singleton pregnancies and 1 twin pregnancy, there were 13 live newborns (65%) and 7 stillbirths (35%). Among liveborn neonates, 5-minute Apgar score was ≤5 in 54%, and among cases with umbilical cord blood gases, pH ≤7.1 was found in 78% and base deficit ≥10 mEq/L in 75%. Positive COVID-19 tests were found in 62% of liveborn infants. Clinicians should be alert to the possibility of disseminated intravascular coagulation when a COVID-19 patient complains of decreased fetal movement in the early third trimester. If time allows, we recommend evaluation of coagulation studies and ordering of blood products for massive transfusion protocols before cesarean delivery if fetal tracing is nonreassuring.

Sections du résumé

BACKGROUND BACKGROUND
Hypercoagulability frequently complicates moderate or severe COVID-19 and can result in venous thromboembolism, arterial thrombosis, or microvascular thrombosis. Disseminated intravascular coagulation, however, is uncommon.
OBJECTIVE OBJECTIVE
We sought to describe the clinical presentation and outcome in a series of pregnant patients with mild or asymptomatic COVID-19 who had disseminated intravascular coagulation.
STUDY DESIGN METHODS
This was a retrospective case series. Cases were solicited via e-mails targeted to obstetrical providers in the Mednax National Medical Group and a restricted maternal-fetal medicine Facebook page. Inclusion criteria were: hospital admission during pregnancy, positive test for SARS-CoV-2 within 2 weeks of admission, and maternal disseminated intravascular coagulation defined as ≥2 of the following: platelet count ≤100,000 per mm
RESULTS RESULTS
Inclusion criteria were met in 19 cases from October 2020 through December 2021. Of these, 18 had not received any COVID-19 vaccine, and 1 had unknown vaccination status. Median gestational age on hospital admission was 30 weeks (interquartile range, 29-34 weeks). The main presenting symptom or sign was decreased fetal movement (56%) or nonreassuring fetal heart rate pattern (16%). COVID-19 was asymptomatic in 79% of cases. Two of the 3 defining coagulation abnormalities were found in 89% of cases and all 3 in the remaining 11%. Aspartate aminotransferase was elevated in all cases and ≥2 times the upper normal limit in 69%. Only 2 cases (11%) had signs of preeclampsia other than thrombocytopenia or transaminase elevation. Delivery was performed on the day of admission in 74% and on the next day in the remaining 26%, most often by cesarean delivery (68%) under general anesthesia (62%) because of nonreassuring fetal heart rate pattern (63%). Postpartum hemorrhage occurred in 47% of cases. Blood product transfusions were given in 95% of cases, including cryoprecipitate (89% of cases), fresh/frozen plasma (79%), platelets (68%), and red cells (63%). Placental histopathology was abnormal in 82%, with common findings being histiocytic intervillositis, perivillous fibrin deposition, and infarcts or necrosis. Among the 18 singleton pregnancies and 1 twin pregnancy, there were 13 live newborns (65%) and 7 stillbirths (35%). Among liveborn neonates, 5-minute Apgar score was ≤5 in 54%, and among cases with umbilical cord blood gases, pH ≤7.1 was found in 78% and base deficit ≥10 mEq/L in 75%. Positive COVID-19 tests were found in 62% of liveborn infants.
CONCLUSION CONCLUSIONS
Clinicians should be alert to the possibility of disseminated intravascular coagulation when a COVID-19 patient complains of decreased fetal movement in the early third trimester. If time allows, we recommend evaluation of coagulation studies and ordering of blood products for massive transfusion protocols before cesarean delivery if fetal tracing is nonreassuring.

Identifiants

pubmed: 36168543
doi: 10.1016/j.xagr.2022.100110
pii: S2666-5778(22)00059-4
pmc: PMC9502436
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100110

Informations de copyright

© 2022 The Authors.

Références

PLoS One. 2020 Apr 16;15(4):e0230295
pubmed: 32298273
JAMA Netw Open. 2020 Dec 1;3(12):e2030455
pubmed: 33351086
Pediatr Dev Pathol. 2021 Jan-Feb;24(1):10-11
pubmed: 33023403
J Clin Invest. 2020 Sep 1;130(9):4947-4953
pubmed: 32573498
Arch Pathol Lab Med. 2021 Nov 1;145(11):1341-1349
pubmed: 34338723
Nat Commun. 2020 Jul 14;11(1):3572
pubmed: 32665677
Am J Obstet Gynecol. 2022 Feb;226(2):177-186
pubmed: 34534497
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Am J Obstet Gynecol. 2021 Mar;224(3):298.e1-298.e8
pubmed: 32853537
Ultrasound Obstet Gynecol. 2020 Nov;56(5):773-776
pubmed: 32853442
JAMA. 2022 Feb 22;327(8):748-759
pubmed: 35129581
PLoS One. 2014 Apr 11;9(4):e93240
pubmed: 24728139
MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-1645
pubmed: 34818318
Crit Care Med. 2020 Sep;48(9):1358-1364
pubmed: 32467443
Placenta. 2021 Jan 15;104:261-266
pubmed: 33465727
J Thromb Haemost. 2020 Jul;18(7):1648-1652
pubmed: 32302459
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Pediatr Dev Pathol. 2002 Mar-Apr;5(2):159-64
pubmed: 11910510
Arch Pathol Lab Med. 2022 Jun 1;146(6):660-676
pubmed: 35142798
Sci Rep. 2022 Jan 18;12(1):942
pubmed: 35042979
Lancet. 2021 Jun 12;397(10291):2226-2228
pubmed: 34119049
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
Intern Emerg Med. 2021 Mar;16(2):309-312
pubmed: 33368021
Am J Obstet Gynecol. 2022 Jan;226(1):68-89.e3
pubmed: 34302772
Am J Obstet Gynecol. 2016 Oct;215(4):408-12
pubmed: 27372270
JAMA. 2022 Feb 8;327(6):580-581
pubmed: 35133427
J Thromb Haemost. 2020 Nov;18(11):3086-3098
pubmed: 32846051
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Placenta. 2021 Sep 1;112:97-104
pubmed: 34329973
BMC Pregnancy Childbirth. 2021 Feb 5;21(1):108
pubmed: 33546624
Am J Reprod Immunol. 2013 Oct;70(4):285-98
pubmed: 23905710
J Infect Dis. 2022 Mar 2;225(5):754-758
pubmed: 35024844
Am J Obstet Gynecol MFM. 2022 May;4(3):100577
pubmed: 35114422
Heart Lung. 2021 Mar-Apr;50(2):357-360
pubmed: 33524866
Thromb Res. 2021 May;201:23-29
pubmed: 33631519
J Thromb Haemost. 2021 Oct;19(10):2539-2545
pubmed: 34260818
Obstet Gynecol. 2021 Apr 1;137(4):571-580
pubmed: 33560778
Arch Pathol Lab Med. 2016 Jul;140(7):698-713
pubmed: 27223167
Clin Respir J. 2021 Dec;15(12):1259-1274
pubmed: 34399021
Acta Obstet Gynecol Scand. 2022 Apr;101(4):461-470
pubmed: 35213734
Am J Obstet Gynecol. 2015 Oct;213(4):452-63
pubmed: 25840271
Circulation. 2020 Jul 14;142(2):129-132
pubmed: 32658609
Lancet Digit Health. 2022 Feb;4(2):e95-e104
pubmed: 35034863
Blood. 2020 Jul 23;136(4):489-500
pubmed: 32492712

Auteurs

Jeanette Carpenter (J)

Obstetrix Medical Group of the Mountain States, Salt Lake City, UT.

C Andrew Combs (CA)

Pediatrix Center for Research, Education, Quality, and Safety, Sunrise, FL.

Bronwen Kahn (B)

Obstetrix Medical Group of Colorado, Denver, CO.

Kimberly Maurel (K)

Pediatrix Center for Research, Education, Quality, and Safety, Sunrise, FL.

Reese Clark (R)

Pediatrix Center for Research, Education, Quality, and Safety, Sunrise, FL.

Classifications MeSH